Please login to the form below

Not currently logged in
Email:
Password:

Boehringer/ Ablynx candidate for Alzheimer's

Ablynx has announced that Boehringer Ingelheim has selected a Nanobody lead candidate for further development for treating Alzheimer's disease

Ablynx has announced that Boehringer Ingelheim has selected a Nanobody lead candidate for further development for the treatment of Alzheimer's disease.

This is the first lead candidate emerging from the Alzheimer's disease collaboration between Ablynx and Boehringer Ingelheim, and will result in a €2m milestone payment to Ablynx.

In January 2007, Boehringer Ingelheim and Ablynx announced that they had entered into a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies, worth a possible $265m in milestone payments plus undisclosed royalties. Boehringer Ingelheim is solely responsible for the development, manufacture and commercialisation of any products resulting from the research collaboration.

"Ablynx's delivery of this potentially 'first-in-class' Nanobody candidate for the treatment of Alzheimer's disease highlights the speed at which we progressed from initiation of the discovery programme in 2007 to this stage of development for a very challenging target," said Dr Edwin Moses, CEO and chairman of Ablynx.

Moses added: "This lead candidate demonstrates the power of the Nanobody platform in addressing a complex disease such as Alzheimer's."

24th May 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

COVID-19 is redefining the value of ‘critical jobs’: An opportunity for social care?
...
How to keep your weight under control during lockdown
...
Brands stepping up to show solidarity during COVID-19
The brands that are stepping up to show solidarity during COVID-19 will be those that are remembered long after pandemic passes....

Infographics